Mental Health as a Priority for Brazilians in 2026: the rise of innovative therapies grounded in scientific evidence

Mental health is no longer a peripheral topic in public debate. It has moved to the center of discussions about quality of life, productivity, public policy, and innovation investment. Recent data indicate that a significant share of Brazilians intend to increase their spending on mental health in the coming years, reflecting a deep behavioral shift: caring for the mind is now seen as essential as caring for the body.

This movement follows a global trend: people are becoming more informed, comparing therapeutic options, and evaluating risks, benefits, and real-life impact. It is no longer just about seeking treatment — it is about seeking quality of life, safety, and predictability of outcomes.

This new landscape creates fertile ground for innovative therapies — especially those supported by scientific evidence — capable of addressing not only clinical criteria but also the practical expectations of the modern patient.

Mental health as a structural — and personal — issue in contemporary society

Mental disorders are among the leading causes of disability worldwide. Depression, anxiety, and substance-related disorders affect hundreds of millions of people and generate impacts far beyond individual suffering. They affect relationships, job performance, income, and autonomy.

For this reason, mental health is no longer only a medical matter. It is a daily life matter. The cost is not only clinical — it is social and economic. For individuals, it is functional: being able to sleep, work, relate, and make decisions clearly.

In this context, demand is growing for solutions that not only reduce symptoms but enable people to function better in everyday life, with lower physiological burden and a better therapeutic experience — ideally supported by reliable scientific evidence.

The new mental health consumer: more informed, more selective

The behavior of people seeking mental health care has changed. Patients are no longer passive — they compare options. They research, ask questions, read labels, investigate side effects, and discuss alternatives.

Beyond clinical efficacy, decision criteria now include:

• quality of life during treatment

• tolerability

• cognitive and functional impact

• perceived risk of dependence

• need for chronic use

• perception of “natural vs. chemical” approaches

• data transparency

• grounding in scientific evidence

There is also a growing interest in solutions perceived as more natural or biologically integrated — provided they are supported by trustworthy data. This does not eliminate the role of traditional pharmacology, but it expands the space for science-based innovation.

Where current treatments still fail in the patient experience

Available psychiatric treatments have delivered important advances, but they still present relevant limitations from the patient’s perspective.

A significant portion of people with depression do not respond adequately to first-line therapies. Others require multiple treatment attempts before finding an effective approach. This process can be long and exhausting.

In addition, factors frequently reported by patients influence adherence:

• delayed onset of effect

• side effects that affect sleep, energy, and libido

• emotional blunting in some cases

• need for continuous use

• concern about dependence in certain drug classes

In practice, many people discontinue treatment not only due to lack of efficacy, but due to poor tolerability or negative impact on quality of life.

This scenario reinforces the need for new approaches — ideally developed with strong scientific evidence — that combine efficacy, safety, and better treatment experience.

Innovative therapies: what changes in real life for patients

Recent advances in neuroscience have opened space for new therapeutic approaches that go beyond symptom suppression and aim to modulate brain circuits associated with mood, cognition, and behavior.

From the patient’s perspective, what makes these therapies innovative is not only their mechanism of action, but their potential for:

• more consistent response

• lower burden of adverse effects

• more targeted protocols

• better functional impact

• potential reduction in chronic use

• integration with structured clinical supervision

These new development pathways follow rigorous research protocols and are evaluated through scientific evidence generated in preclinical and clinical studies — a key factor in turning innovation into reliable care.

How patients evaluate safety and trust in new therapies

For mental health consumers, trust no longer comes only from tradition — it comes from clarity. Patients want to know:

• are there clinical studies?

• are results reproducible?

• are risks known?

• is there regulatory oversight?

• are the data transparent?

This is where scientific evidence plays a critical role — not as technical jargon, but as a patient protection mechanism. It acts as a filter against empty promises and untested solutions.

Rather than being the center of the narrative, scientific evidence functions as the invisible foundation of trust, supporting clinical and regulatory decisions.

Regulation and patient protection

Regulatory agencies exist to ensure that new therapies meet standards of quality, safety, and efficacy. For patients, this means lower exposure to unknown risks and greater predictability of outcomes.

The requirement for robust scientific evidence and quality control is not a barrier to innovation — it is a condition for innovation to be trustworthy and scalable.

Why the market is watching mental health

Growing interest in mental health is also economic. Investors recognize:

• rising demand

• unresolved structural need

• space for innovation

• active consumer search

• demand for more tolerable and effective solutions

Capital tends to prioritize solutions that combine three elements:

1) measurable impact 2) perceived patient benefit

3) foundation in scientific evidence

Science, biodiversity, and new therapeutic frontiers

Brazil brings together biodiversity, scientific capacity, and research infrastructure capable of supporting new therapeutic pathways in mental health. The integration of biotechnology, pharmacology, and neuroscience opens room for innovation with its own scientific identity — provided it is supported by scientific evidence, ethics, and regulation.

Conclusion: mental health innovation must work for the user

The new mental health agenda is not only about treating diseases — it is about improving lives. Modern patients want efficacy, but they also want tolerability, predictability, and quality of life.

The future of the sector will be defined by therapies that combine:

• clinical results

• good user experience

• safety

• regulations

• cientific evidence

• real functional impact

Connecting science and innovation

If you believe the future of mental health depends on innovative therapies grounded in scientific evidence, with strong regulatory rigor and focus on safety and quality of life, it is worth getting to know Brazilian initiatives that are transforming research into real therapeutic solutions. Ayamed operates precisely at this intersection, developing prescription medicines based on science, pharmaceutical innovation, and sustainability, focused on addressing major mental health challenges.